IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. (9th June 2020)

• Record Type: Journal Article
• Authors: Mao, Xue‐Han; Zhuang, Jun‐Ling; Zhao, Duo‐Duo; Li, Xiao‐Qing; Du, Xin; Hao, Mu; Xu, Yan; Yan, Yu‐Ting; Liu, Jia‐Hui; Fan, Hui‐Shou; Sui, Wei‐Wei; Deng, Shu‐Hui; Li, Cheng‐Wen; Zhao, Jia‐Wei; Yi, Shu‐Hua; Du, Chen‐Xing; Zou, De‐Hui; Li, Zeng‐Jun; Zhao, Yao‐Zhong; Zhan, Feng‐Huang; Tai, Yu‐Tzu; Fang, Bai‐Jun; Song, Yong‐Ping; Wang, Jian‐Xiang; Anderson, Kenneth C.; Qiu, Lu‐Gui; An, Gang
• Is Part Of: European journal of haematology. Volume 105:Number 3(2020)
• Page Start: 326
• Page End: 334
• Publication Date: 2020-06-09
• Subjects: cytogenetics -- IgH translocation -- multiple myeloma -- prognosis -- unknown partner chromosomes; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13440
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Background: In multiple myeloma (MM), impact of specific chromosomal translocations involving IgH (14q21 locus, including t(4;14), t(11;14), and t(14;16)) has been explored extensively. However, over 15% MM patients harboring IgH translocation with undefined partners have long been ignored. Methods: A prospective non‐randomized cohort study with a total of 715 newly‐diagnosed MM cases was conducted, 13.6% of whom were t(14;undefined) positive. The whole cohort was divided into four groups: no IgH split (47.7%); t(14;undefined) (13.6%); t(11;14) (17.6%); and t(4;14) or t(14;16) group (21.1%). Results: Median OS for the four groups was 84.2, not reached (NR), 58.7, and 44.2 months, respectively, with P values for t(14;undefined) vs no IgH split, t(11;14), and t(4;14)/t(14;16) groups of 0.197, 0.022, and 0.001, respectively. In bortezomib‐based group, the survival advantage gained by t(14;undefined) group was much more significant compared to t(11;14) and t(4;14)/t(14;16) groups. Importantly, t(14;undefined) turned out to be an independent predictive factor for longer OS of MM patients in multivariate analysis, especially in the context of bortezomib treatment. Similar results were also observed in the PUMCH external validation cohort. Conclusion: Collectively, our data confirmed and externally validated the favorable prognosis of the t(14;undefined) groups, especially in the era of novel agents.